Mawer Investment Management Ltd. purchased a new stake in shares of Repligen Corporation (NASDAQ:RGEN – Free Report) during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 29,300 shares of the biotechnology company’s stock, valued at approximately $5,632,000.
A number of other institutional investors and hedge funds have also made changes to their positions in RGEN. Aberdeen Group plc raised its position in shares of Repligen by 45.9% during the 3rd quarter. Aberdeen Group plc now owns 70,638 shares of the biotechnology company’s stock valued at $13,579,000 after buying an additional 22,234 shares in the last quarter. William Blair Investment Management LLC increased its stake in Repligen by 57.7% during the third quarter. William Blair Investment Management LLC now owns 1,243,415 shares of the biotechnology company’s stock worth $239,022,000 after acquiring an additional 454,844 shares during the last quarter. Russell Investments Group Ltd. raised its position in Repligen by 46.1% during the third quarter. Russell Investments Group Ltd. now owns 40,848 shares of the biotechnology company’s stock valued at $7,852,000 after purchasing an additional 12,891 shares during the period. Eurizon Capital SGR S.p.A. lifted its stake in shares of Repligen by 21.2% in the 3rd quarter. Eurizon Capital SGR S.p.A. now owns 583 shares of the biotechnology company’s stock valued at $114,000 after purchasing an additional 102 shares during the last quarter. Finally, New Mexico Educational Retirement Board lifted its stake in shares of Repligen by 12.3% in the 3rd quarter. New Mexico Educational Retirement Board now owns 11,900 shares of the biotechnology company’s stock valued at $2,288,000 after purchasing an additional 1,300 shares during the last quarter. 97.64% of the stock is owned by hedge funds and other institutional investors.
Repligen Stock Performance
RGEN stock opened at $167.79 on Monday. Repligen Corporation has a 12 month low of $100.99 and a 12 month high of $198.87. The firm’s 50-day moving average is $177.15 and its 200 day moving average is $145.67. The company has a market capitalization of $10.73 billion, a PE ratio of -798.96, a P/E/G ratio of 2.88 and a beta of 1.11. The company has a debt-to-equity ratio of 0.27, a current ratio of 9.88 and a quick ratio of 8.43.
Repligen (NASDAQ:RGEN – Get Free Report) last issued its earnings results on Tuesday, October 27th. The biotechnology company reported $0.53 EPS for the quarter, topping analysts’ consensus estimates of $0.46 by $0.07. The business had revenue of $209.31 million for the quarter, compared to the consensus estimate of $206.70 million. Repligen had a negative net margin of 1.47% and a positive return on equity of 5.49%. The company’s revenue for the quarter was up 10.9% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.46 EPS. On average, research analysts anticipate that Repligen Corporation will post 2.07 EPS for the current year.
Analyst Upgrades and Downgrades
RGEN has been the subject of a number of recent research reports. UBS Group reiterated a “buy” rating on shares of Repligen in a report on Tuesday, September 29th. Barclays increased their target price on shares of Repligen from $175.00 to $225.00 and gave the company an “overweight” rating in a research note on Wednesday, October 7th. Weiss Ratings lowered shares of Repligen from a “hold (c)” rating to a “sell (d+)” rating in a report on Monday, November 2nd. Canaccord Genuity Group lifted their price target on shares of Repligen from $145.00 to $180.00 and gave the stock a “hold” rating in a research note on Monday, October 19th. Finally, JPMorgan Chase & Co. upped their price target on shares of Repligen from $165.00 to $175.00 and gave the company an “overweight” rating in a report on Wednesday, July 29th. Two investment analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $178.57.
Get Our Latest Stock Report on Repligen
Repligen Company Profile
Repligen is a life sciences company that develops and supplies technologies used in the manufacture of biologic medicines. Its products support biopharmaceutical companies and contract manufacturers in producing treatments such as monoclonal antibodies, vaccines and gene therapies. The company’s offerings span several stages of bioprocessing, including filtration, chromatography, fluid management and process analytics. Its products include filtration systems and single-use components, chromatography solutions and instruments that help monitor and control manufacturing processes.
See Also
- Five stocks we like better than Repligen
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Want to see what other hedge funds are holding RGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Repligen Corporation (NASDAQ:RGEN – Free Report).
Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.
